SOURCE: The Bedford Report

The Bedford Report

February 02, 2011 11:25 ET

"Unconstitutional" Healthcare Reform Benefits Avanir & Somaxon

The Bedford Report Provides Analyst Research on Avanir & Somaxon

NEW YORK, NY--(Marketwire - February 2, 2011) - The healthcare sector received surprising news to start off the week when a federal judge in Florida became the second US judge to declare the healthcare reform law unconstitutional. Reports suggest this is the biggest legal challenge yet to federal authority to enact the law. President Obama's health care reform has been receiving its share of scrutiny already in 2011, and while small cap drug makers and biotech companies have mostly warmed up to the idea of reform, GOP opponents are making their cases to have the law repealed. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides research reports on Avanir Pharmaceuticals (NASDAQ: AVNR) and Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX). Access to the full company reports can be found at:

www.bedfordreport.com/2011-02-AVNR

www.bedfordreport.com/2011-02-SOMX

Last month The House of Representatives voted to repeal President Obama's healthcare reform law. The measure passed 245-189, with three Democrats joining all of the House's 242 Republicans to support overturning the measure signed into law by Obama ten months ago. Although the repeal is largely symbolic -- Obama has made it clear he would veto any such measure that reached his desk -- and unlikely to be approved in the Democratic-controlled Senate, it could give momentum to legal challenges against the law (as seen in Florida on Monday).

Small cap biotech companies and drug manufacturers were considered some of the "winners" from healthcare reform. The bill enables the FDA to create a pathway for approval of biosimilar products, providing 12 years of market exclusivity to brand-name product. According to Biotechnology Industry Organization president and CEO Jim Greenwood, reform would lead to "new and improved treatments, cures, and cost-savings for patients while driving job growth in our industry and maintaining our nation's global leadership in biotechnology innovation."

The Bedford Report releases regular market updates on the Healthcare sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Analysts argue that Obama has been beneficial to small cap biotech companies and speciality drug makers such as Avanir and Somaxon. In the latter half of 2010, the Obama administration pressed congress to revamp a research and development tax credit by increasing it by about 20 percent and make it permanent. The Pharmaceutical Research and Manufacturers of America, PhRMA, as well as the Advanced Medical Technology Association expressed support for the tax credit.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information